REMSleep 510K
Rhea-AI Summary
REMSleep Holdings, Inc. (OTC: RMSL) has engaged Empirical Technologies Corp to expedite its 510K submission, addressing frustrations with previous delays. This partnership aims to enhance the submission process, with ETC boasting a 100% success rate and approvals 20% to 40% quicker than industry norms. The company received a patent approval in April 2021 and is preparing to launch its marketing program post-510K clearance. Future products are in development, expected to be released more efficiently.
Positive
- Engaged Empirical Technologies Corp to streamline 510K submission process.
- ETC has a 100% success rate with 510K filings.
- 510K submissions through ETC are approved 20% to 40% faster than average.
- Received patent approval for utility patent in April 2021.
Negative
- Frustration with previous 510K submission progress.
News Market Reaction – RMSL
On the day this news was published, RMSL gained 0.96%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
REMSLEEP HOLDINGS, INC. ENGAGES NEW REGULATORY AGENCY
Tampa, FL, June 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- REMSleep Holdings, Inc. (OTC: RMSL) (the “Company”) announces the company has engaged Empirical Technologies Corp to complete its 510K process. Remsleep has become frustrated with the progress of its 510K submission. Partnering with ETC will ensure the Remsleep 510K submission will be streamlined and put the company’s 510K submission on the right track. Remsleep plans to engage ETC with all future regulatory needs. 510K submissions through ETC have record of approval
Remsleep received patent approval of its utility patent application April 2021.
The company is poised to launch marketing program as soon as 510k clearance is complete. The company continues to work on new product and expects to release future product with far greater ease and timely manner.
Forward-looking Statements. This press release may contain forward-looking statements regarding Company. All statements, other than statements of historical fact included herein, are "forward-looking statements" including statements regarding the Company’s future prospects and risks in investing in Company’s common stock. These statements are based upon the Company's current expectations and speak only as of the date hereof. Financial performance in one period does not necessarily mean continued or better performance in the future. The Company's actual results in any endeavor may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, which factors or uncertainties may be beyond our ability to foresee or control. Other risk factors include the status of the Company's common stock as a "penny stock" and those risk factors stated in reports filed with the U.S. Securities and Exchange Commission or “SEC” on its EDGAR website (URL: www.sec.gov).
Tom Wood
912-590-2001
twood@remsleep.com
FAQ
What is the latest update on REMSleep Holdings, Inc. (RMSL)?
Who has REMSleep Holdings partnered with for regulatory needs?
What is the success rate of Empirical Technologies Corp's 510K filings?
When did REMSleep Holdings receive patent approval?
How much faster are 510K approvals with Empirical Technologies Corp?
